Invention Grant
- Patent Title: Membrane fusion inhibitor
- Patent Title (中): 膜融合抑制剂
-
Application No.: US12865360Application Date: 2009-02-02
-
Publication No.: US08952055B2Publication Date: 2015-02-10
- Inventor: Kunihiro Kaihatsu , Shuichi Mori , Tomo Daidoji , Nobuo Kato , Shinya Miyake
- Applicant: Kunihiro Kaihatsu , Shuichi Mori , Tomo Daidoji , Nobuo Kato , Shinya Miyake
- Applicant Address: JP Osaka
- Assignee: Protectea, Ltd.
- Current Assignee: Protectea, Ltd.
- Current Assignee Address: JP Osaka
- Agency: Hamre, Schumann, Mueller & Larson, P.C.
- Priority: JP2008-023196 20080201
- International Application: PCT/JP2009/051721 WO 20090202
- International Announcement: WO2009/096581 WO 20090806
- Main IPC: A61K31/35
- IPC: A61K31/35 ; A61K31/22 ; A61K31/353 ; A61K45/06 ; C07D311/62

Abstract:
The present invention provides a pharmaceutical composition that has excellent safety and targets a different step in the virus propagation cycle than conventional pharmaceutical compositions, applicable as an antiviral agent. A pharmaceutical composition containing an epigallocatechin gallate derivative represented by the following chemical formula (1), an isomer thereof, or a salt thereof is prepared. This can be used as a membrane fusion inhibitor that inhibits viral membrane fusion. In the following formula, R1 to R6 are each a hydrogen atom, halogen, sodium, potassium, or a straight-chain or branched, saturated or unsaturated acyl group and may be identical to or different from one another. The acyl group may be substituted further with one or more substituents. At least one of R1 to R6 is the acyl group. R7 to R16 are each a hydrogen atom, halogen, sodium, or potassium and may be identical to or different from one another.
Public/Granted literature
- US20110003889A1 MEMBRANE FUSION INHIBITOR Public/Granted day:2011-01-06
Information query